Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon
Research output: Contribution to journal › Journal article › peer-review
Glucagon-like peptide 2 (GLP-2) is a newly discovered intestinotrophic hormone. We have recently reported that a 5-week GLP-2 treatment improved the intestinal absorptive capacity of short-bowel patients with no colon. Additionally, GLP-2 treatment was associated with changes in body composition that included a significant increase in total body bone mass. This article describes the effect of GLP-2 on spinal and hip bone mineral density (BMD) and biochemical markers of bone turnover in these patients.
|Journal||Scandinavian Journal of Gastroenterology|
|Number of pages||7|
|Publication status||Published - 1 Apr 2002|
- Absorptiometry, Photon, Adult, Alkaline Phosphatase, Amino Acids, Bone Density, Bone Diseases, Metabolic, Bone Remodeling, Calcium, Female, Gastrointestinal Hormones, Glucagon, Glucagon-Like Peptide 2, Glucagon-Like Peptides, Hormones, Humans, Intestinal Absorption, Male, Middle Aged, Osteocalcin, Osteoporosis, Parathyroid Hormone, Peptides, Pilot Projects, Short Bowel Syndrome, Vitamin D